Abstract
Prions are renowned for their role in neurodegenerative diseases in humans and animals. These are manifested as transmissible spongiform encephalopathies (TSEs) that result from the conversion of the normal glycosylphosphatidylinositol (GPI) anchored cellular prion protein (PrPc) to a misfolded, aggregated and pathogenic form, prion protein scrapie (PrPSc) via a post-translational process followed by the accumulation of PrP>Sc within the central nervous system.
New research in this area has demonstrated that PrP is over-expressed in a variety of cancers including gastric, pancreatic and breast cancers, affecting the growth and invasiveness of these cancers as well as playing an important role in the acquisition of multi-drug resistant (MDR) gastric cancer. Prion-like doppel protein (Dpl), sharing 25% amino acid sequence homology to PrP and whose function remains elusive, has also been shown to exhibit a high level of expression in a number of cancers including acute myeloid leukemia’s, myelodysplastic syndromes, gastric adenocarcinoma, anaplastic meningioma and astrocytomas. Furthermore, the tumour suppressor protein, p53, already known for its involvement in cancer development, has recently been shown to display prion-like tendencies.
This review provides an overview of prions and prion-like proteins in mammals discussing their structure, function and role in cell function and disease. Furthermore, current research progress on the role of prion/prion-like proteins in the development, progression, and drug resistance of various cancers will be summarized. Potential implications for future development of new therapeutic treatments targeting prion and prion-like proteins will be discussed.
Keywords: Epigenetic, PRND, PRNP, protein misfolding, tumour marker.
Current Cancer Drug Targets
Title:Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Volume: 13 Issue: 8
Author(s): Caroline Hinton, Helma Antony, Saeed M. Hashimi, Alan Munn and Ming Q. Wei
Affiliation:
Keywords: Epigenetic, PRND, PRNP, protein misfolding, tumour marker.
Abstract: Prions are renowned for their role in neurodegenerative diseases in humans and animals. These are manifested as transmissible spongiform encephalopathies (TSEs) that result from the conversion of the normal glycosylphosphatidylinositol (GPI) anchored cellular prion protein (PrPc) to a misfolded, aggregated and pathogenic form, prion protein scrapie (PrPSc) via a post-translational process followed by the accumulation of PrP>Sc within the central nervous system.
New research in this area has demonstrated that PrP is over-expressed in a variety of cancers including gastric, pancreatic and breast cancers, affecting the growth and invasiveness of these cancers as well as playing an important role in the acquisition of multi-drug resistant (MDR) gastric cancer. Prion-like doppel protein (Dpl), sharing 25% amino acid sequence homology to PrP and whose function remains elusive, has also been shown to exhibit a high level of expression in a number of cancers including acute myeloid leukemia’s, myelodysplastic syndromes, gastric adenocarcinoma, anaplastic meningioma and astrocytomas. Furthermore, the tumour suppressor protein, p53, already known for its involvement in cancer development, has recently been shown to display prion-like tendencies.
This review provides an overview of prions and prion-like proteins in mammals discussing their structure, function and role in cell function and disease. Furthermore, current research progress on the role of prion/prion-like proteins in the development, progression, and drug resistance of various cancers will be summarized. Potential implications for future development of new therapeutic treatments targeting prion and prion-like proteins will be discussed.
Export Options
About this article
Cite this article as:
Hinton Caroline, Antony Helma, Hashimi M. Saeed, Munn Alan and Wei Q. Ming, Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance, Current Cancer Drug Targets 2013; 13 (8) . https://dx.doi.org/10.2174/156800961131300092
DOI https://dx.doi.org/10.2174/156800961131300092 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mass Spectrometric Imaging of the Nervous System
Current Pharmaceutical Design The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design Caffeic Acid, A Versatile Pharmacophore: An Overview
Mini-Reviews in Medicinal Chemistry Proceedings of the 1<sup>st</sup> Puerto Rico Biobanking Workshop
Reviews on Recent Clinical Trials Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Methods of Screening-Purification and Antimicrobial Potentialities of Bacteriocin in Health Care
Current Drug Metabolism Chemokines and Breast Cancer: A Gateway to Revolutionary Targeted Cancer Treatments?
Current Medicinal Chemistry Long Term Prognosis in IgG4-Related Systemic Disease (ISD)
Current Immunology Reviews (Discontinued) Chemokines as Therapeutic Targets in Non-Small Cell Lung Cancer: Update
Medicinal Chemistry Reviews - Online (Discontinued) Synthesis and Anti-cancer Activities of Apigenin Derivatives
Medicinal Chemistry Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Postmortem-Assessed Impairment of Neuronal Activity in Depression: The Dominant Impact of Suicide
CNS & Neurological Disorders - Drug Targets Anticancer Advances of Matrine and Its Derivatives
Current Pharmaceutical Design Current Management of Chordoma
Current Drug Therapy Plasma-Free Amino Acid Profiling of Nasal Polyposis Patients
Combinatorial Chemistry & High Throughput Screening Meet Our Editorial Board Member
Current Drug Targets Modelling and Dosimetry for Alpha-Particle Therapy
Current Radiopharmaceuticals Graphical Abstracts
Letters in Drug Design & Discovery